Financial Analysis: Dianthus Therapeutics (NASDAQ:DNTH) vs. Moderna (NASDAQ:MRNA)

Dianthus Therapeutics (NASDAQ:DNTH) and Moderna (NASDAQ:MRNA) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their dividends, valuation, institutional ownership, analyst recommendations, profitability, risk and earnings.

Insider and Institutional Ownership

47.5% of Dianthus Therapeutics shares are held by institutional investors. Comparatively, 75.3% of Moderna shares are held by institutional investors. 3.0% of Dianthus Therapeutics shares are held by insiders. Comparatively, 10.8% of Moderna shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Volatility & Risk

Dianthus Therapeutics has a beta of 1.18, indicating that its stock price is 18% more volatile than the S&P 500. Comparatively, Moderna has a beta of 1.05, indicating that its stock price is 5% more volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of current recommendations and price targets for Dianthus Therapeutics and Moderna, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Dianthus Therapeutics	1	0	12	1	2.93
Moderna	5	11	2	0	1.83

Dianthus Therapeutics currently has a consensus price target of $117.82, suggesting a potential upside of 49.36%. Moderna has a consensus price target of $36.60, suggesting a potential downside of 33.94%. Given Dianthus Therapeutics’ stronger consensus rating and higher possible upside, analysts plainly believe Dianthus Therapeutics is more favorable than Moderna.

Profitability

This table compares Dianthus Therapeutics and Moderna’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Dianthus Therapeutics	-12,998.50%	-27.30%	-25.91%
Moderna	-143.55%	-26.64%	-19.32%

Earnings and Valuation

This table compares Dianthus Therapeutics and Moderna”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Dianthus Therapeutics	$2.04 million	2,113.91	-$162.34 million	($4.13)	-19.10
Moderna	$1.94 billion	11.31	-$2.82 billion	($8.15)	-6.80

Dianthus Therapeutics has higher earnings, but lower revenue than Moderna. Dianthus Therapeutics is trading at a lower price-to-earnings ratio than Moderna, indicating that it is currently the more affordable of the two stocks.

Summary

Dianthus Therapeutics beats Moderna on 8 of the 15 factors compared between the two stocks.

About Dianthus Therapeutics

Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc. was founded in 2019 and is headquartered in New York, New York.

About Moderna

Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; rare disease intracellular therapeutics; and inhaled pulmonary therapeutics. It has strategic alliances and collaborations with AstraZeneca; Merck & Co., Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Chiesi Farmaceutici S.p.A.; Metagenomi, Inc.; Carisma Therapeutics, Inc.; CytomX Therapeutics; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; and The Bill & Melinda Gates Foundation. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.